Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer

CompletedOBSERVATIONAL
Enrollment

103

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

February 1, 2020

Conditions
Pancreatic CancerMetastatic Pancreatic Cancer
Interventions
DRUG

nab paclitaxel plus gemcitabine

Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Bundang CHA Hospital

OTHER

collaborator

Ulsan University Hospital

OTHER

lead

Asan Medical Center

OTHER